Payer perspectives on pharmacogenomics testing and drug development

Pharmacogenomics

Volumn 10, Issue 1, 2009, Pages 149-151

  Epstein, Robert S ^a   Frueh, Felix W ^a   Geren, Dawn ^b   Hummer, Doris ^c   McKibbin, Scott ^c   O'Connor, Susan ^a   Randhawa, Gurvaneet ^c   Zelman, Benjamin ^a  

^a Medco Health Solutions   (United States)

^b United Parcel Service   (United States)

^c BWXTY12 ^*  (United States)

Author keywords

Diagnostics; Genetics; Molecular; Payers; Pharmacogenomics; Reimbursement

Indexed keywords

DRUG;

ARTICLE; CLINICAL RESEARCH; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH INSURANCE; PHARMACOGENOMICS; POLITICAL PARTICIPATION; POPULATION RESEARCH; PRODUCT DEVELOPMENT; RISK ASSESSMENT; RISK REDUCTION; TAX; WORKMAN COMPENSATION; DIAGNOSTIC PROCEDURE; DRUG DESIGN; ECONOMICS; HUMAN; PHARMACOGENETICS; PREDICTION AND FORECASTING; REIMBURSEMENT; STANDARD; UNITED STATES;

COST-BENEFIT ANALYSIS; DIAGNOSTIC TECHNIQUES AND PROCEDURES; DRUG DESIGN; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PREDICTIVE VALUE OF TESTS; REIMBURSEMENT MECHANISMS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 62649149433     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.10.1.149     Document Type: Article

References (0)